Abstract
Morbidity and mortality from diabetes mellitus (DM) are serious worldwide concerns. By the year 2030, the estimated number of diabetic patients will reach a staggering 439 million worldwide. Diabetes mellitus type 2 (DM2), which involves disturbances in both insulin secretion and resistance, is the most common form of diabetes and affects approximately 5 to 7% of the world's population. When a patient with DM2 cannot regulate his or her blood glucose levels through diet, weight loss, or exercise, oral medications, such as hypoglycemic agents (i.e., sulphonylureas, biguanides, alpha glucosidase inhibitors and thiazolidinediones), are crucial. Here, we discuss some physiological aspects of P2 receptors on pancreatic β-cells, which express a variety of P2 receptor isoforms. These receptors enhance glucose-dependent insulin release. In addition, we speculate on the potential of purinergic compounds as novel or additional treatments for Type 2 Diabetes mellitus.
Keywords: P2 receptors, Diabetes, Antagonists, Pancreatic B-cells
Current Diabetes Reviews
Title:Modulation of P2 Receptors on Pancreatic β-cells by Agonists and Antagonists: A Molecular Target for Type 2 Diabetes Treatment
Volume: 9 Issue: 3
Author(s): Paulo Anastacio Furtado Pacheco, Leonardo Gomes Braga Ferreira, Luiz Anastacio Alves and Robson Xavier Faria
Affiliation:
Keywords: P2 receptors, Diabetes, Antagonists, Pancreatic B-cells
Abstract: Morbidity and mortality from diabetes mellitus (DM) are serious worldwide concerns. By the year 2030, the estimated number of diabetic patients will reach a staggering 439 million worldwide. Diabetes mellitus type 2 (DM2), which involves disturbances in both insulin secretion and resistance, is the most common form of diabetes and affects approximately 5 to 7% of the world's population. When a patient with DM2 cannot regulate his or her blood glucose levels through diet, weight loss, or exercise, oral medications, such as hypoglycemic agents (i.e., sulphonylureas, biguanides, alpha glucosidase inhibitors and thiazolidinediones), are crucial. Here, we discuss some physiological aspects of P2 receptors on pancreatic β-cells, which express a variety of P2 receptor isoforms. These receptors enhance glucose-dependent insulin release. In addition, we speculate on the potential of purinergic compounds as novel or additional treatments for Type 2 Diabetes mellitus.
Export Options
About this article
Cite this article as:
Anastacio Furtado Pacheco Paulo, Gomes Braga Ferreira Leonardo, Anastacio Alves Luiz and Xavier Faria Robson, Modulation of P2 Receptors on Pancreatic β-cells by Agonists and Antagonists: A Molecular Target for Type 2 Diabetes Treatment, Current Diabetes Reviews 2013; 9 (3) . https://dx.doi.org/10.2174/1573399811309030004
DOI https://dx.doi.org/10.2174/1573399811309030004 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metformin Restrains Pancreatic Duodenal Homeobox-1 (PDX-1) Function by Inhibiting ERK Signaling in Pancreatic Ductal Adenocarcinoma.
Current Molecular Medicine The Role of Tirofiban in the Management of Coronary Artery Disease
Cardiovascular & Hematological Disorders-Drug Targets Indole Alkaloids as New Leads for the Design and Development of Novel DPP-IV Inhibitors for the Treatment of Diabetes
Current Bioinformatics DNA Methylation, An Epigenetic Mode of Gene Expression Regulation in Reproductive Science
Current Pharmaceutical Design Aldose Reductase Enzyme and its Implication to Major Health Problems of the 21st Century
Current Medicinal Chemistry Subject Index To Volume 6
Endocrine, Metabolic & Immune Disorders - Drug Targets Is there a Role for Oral Triple Therapy in Patients with Acute Coronary Syndromes Without Atrial Fibrillation?
Current Vascular Pharmacology Anti-Angiogenesis Activities of Dietary Constituents and Health Foods with Potential Anti-Hepatocellular Carcinoma Activity
Recent Patents on Biomarkers Urtica dioica Extract Inhibits Cell Proliferation and Induces Apoptosis in HepG2 and HTC116 as Gastrointestinal Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Anti-Diabetic Effect of a Flavonoid and Sitosterol - Rich Aqueous Extract of <i>Pleurotus tuberregium</i> Sclerotia in Alloxan-Induced Diabetic Rabbits
Endocrine, Metabolic & Immune Disorders - Drug Targets History, Prevalence and Assessment of Limited Joint Mobility, from Stiff Hand Syndrome to Diabetic Foot Ulcer Prevention: A Narrative Review of the Literature
Current Diabetes Reviews Molecular Mechanisms of Diabetes and Atherosclerosis: Role of Adiponectin
Endocrine, Metabolic & Immune Disorders - Drug Targets Association of Sleep Apnea Syndrome and Diabetes Mellitus
Current Respiratory Medicine Reviews Correlation Between Insulin Levels and Thyroid Hormones in Diabetic Animals After Caffeine Consumption Associated with Exercise
Current Nutrition & Food Science Current Status of Therapeutic Angiogenesis with Protein, Gene and Cell Therapy
Current Drug Therapy Novel Treatments in Diabetic Nephropathy
Current Hypertension Reviews Endothelial Dysfunction in Hyperglycemia as a Trigger of Atherosclerosis
Current Diabetes Reviews Nutrigenomics and Personalized Diet: What are the Anticipated Impacts for Research on Chronic Diseases and Public Health?
Current Pharmacogenomics and Personalized Medicine Therapeutic Angiogenesis by Gene Therapy for Critical Limb Ischemia: Choice of Biological Agent
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Editorial: Resolution of Non-Alcoholic-Steatohepatitis. More than One Drug Needed?
Current Vascular Pharmacology